# US 2025/0155436 A1 · Composition for poc pcr

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0155436 A1
- Document ID: US20250155436A1
- Status: Published application
- Kind: A1
- Application number: 18/838,941
- Filed: 2023-02-15
- Published: 2025-05-15
- Earliest claimed: 2022-02-15
- Assignees: Procomcure Biotech GmbH
- Applicants: Procomcure Biotech GmbH
- Inventors: Kamil ÖNDER
- Web page: https://patentgrep.com/patent/US20250155436A1

## CPC

- G01N 33/56983: {Viruses}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 33/587: {Nanoparticles}
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2333/922: Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.

## Claims

### Claim 1

Liquid composition for the preparation of a biological sample for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by point-of-care (POC) PCR comprising:
a) a chaotropic salt in a concentration ranging from 1 to 90 mM; and
b) one or more RNAse inhibitor.

### Claim 2 (depends on 1)

Composition according to claim 1 wherein the biological sample is saliva and/or nasopharyngeal secret.

### Claim 3 (depends on 1)

Composition according to claim 1 wherein the chaotropic salt is present in a concentration of 1 to 90 mM.

### Claim 4 (depends on 1)

Composition according to claim 1 comprising two or more RNAse inhibitors.

### Claim 5 (depends on 1)

Composition according to claim 1 comprising a recombinant RNAse inhibitor.

### Claim 6 (depends on 1)

Composition according to claim 1 comprising a murine RNAse inhibitor.

### Claim 7 (depends on 1)

Composition according to claim 1 comprising a monoclonal antibody to ribonuclease A.

### Claim 8 (depends on 1)

Composition according to claim 1 comprising monoclonal anti-spike Protein binding and SARS Cov-2 neutralizing antibody.

### Claim 9 (depends on 1)

Composition according to claim 1 comprising nanoparticles.

### Claim 10 (depends on 9)

Composition according to claim 9 comprising nanoparticles which do not sediment in the composition.

### Claim 11 (depends on 1)

Composition according to claim 1 comprising nanoparticles wherein the nanoparticles have a volume average particle diameter of 1 to 500 nm, determined by light scattering method.

### Claim 12 (depends on 1)

Composition according to claim 1 comprising nanoparticles wherein the nanoparticles are iron particles.

### Claim 13 (depends on 1)

Composition according to claim 1 comprising
a) guanidinium salt in a concentration ranging from 1 to 90 mM;
b1) RNAse Inhibitor 1: murine RNAseA inhibitor; and/or;
b2) RNAse Inhibitor 2: anti RNAseA antibody;
c) Covid-19 neutralizing antibody; and
d) iron nanoparticles.

### Claim 14 (depends on 1)

Point-Of-Care (POC) PCR method for the detection of SARS-Cov-2 or mutants thereof comprising the steps:
a) Mixing a biological sample with a composition according to claim 1 to obtain a mixture A,
b) optionally incubating mixture A,
c) mixing mixture A with a PCR reaction mixture comprising one or more of reverse transcriptase, polymerase, PCR buffer, primer and probes for a PCR assay.

### Claim 15 (depends on 14)

Method according to claim 14 wherein step a) is carried out in a container which is adapted to be sealed with a cap wherein said cap has a through hole with a closure element which is separably attached.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

Kit comprising a container containing the composition according to claim 1 and a separate container comprising a PCR reaction mixture comprising one or more of reverse transcriptase, polymerase, PCR buffer, primer and probes for a PCR assay.

### Claim 18 (depends on 1, 17)

Kit according to claim 17 wherein the container comprising the composition according to claim 1 is a container which is sealed with a cap wherein said cap has a through hole with a closure element which is separably attached.

### Claim 19 (depends on 1)

Composition according to claim 1, wherein the chaotropic salt comprises guanidinium thiocyanate.

### Claim 20 (depends on 9)

Composition according to claim 9, wherein the nanoparticles are coated with anti-Spike SARS-Cov-2 antibodies, biotin, protein A, or a combination thereof.

### Claim 21 (depends on 1)

Composition according to claim 1, wherein the iron particles are preferably coated with silica.
